Tag Archives: Dementia Innovation

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Posted on August 3, 2019 by Dementia and Elderly Care News

Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine | Leave a comment

Who and What is the Dementia Envoy? (WDC / Department of Health)

Posted on March 8, 2016 by Dementia and Elderly Care News

Summary The Prime Minister has appointed David Mayhew as the latest Dementia Envoy. Dennis Gillings was the former World Dementia Envoy. “The envoy works with countries, corporations and leaders from around the world, sharing expertise and promoting research and support … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Researchers (mostly), In the News, International, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Academia-Industry Partnerships, Alzheimer’s Research UK (ARUK), British Prime Minister's Office, Challenge on Dementia (David Cameron), Collaborative Projects, Cross-Sector Partnerships, Data Sharing, David Cameron, David Mayhew CBE: Former Chairman of JP Morgan Cazenove, David Mayhew CBE: Vice Chairman of JP Morgan’s Global Investment Bank, David Mayhew CBE: Wellcome Trust Investment Committee, David Mayhew: Chairman of Alzheimer’s Research UK, David Mayhew: Dementia Envoy (2016-), Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Innovation, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Envoy for Dementia Innovation, Global Outlook, Global Social Investment for Dementia, Government Research Funding, International Collaborations, International Programmes, JP Morgan, Knowledge Translation, Leadership, Partnership, Partnership and Collaboration, Partnership Working, Prime Minister's Challenge on Dementia, Prime Minister's Office, Prime Minister’s Dementia Challenge, Research and Innovation, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Alzheimer Report 2014, World Dementia Council, World Dementia Envoy | Leave a comment

World Alzheimer’s Day (BBC News / ARUK / OHE / NHS Choices)

Posted on September 22, 2015 by Dementia and Elderly Care News

Summary To mark World Alzheimer’s Day, life-expectancy and dementia incidence statistics, commissioned from the Office of Health Economics, have been used to arrive at the projection that perhaps one in three people born in the UK this year could develop … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Commissioning, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Management of Condition, Models of Dementia Care, NHS Digital (Previously NHS Choices), Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Ageing Population, Ageing Society, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Behind the Headlines, CFAS I Study, Cognitive Functioning and Ageing Study (CFAS), Costs of Dementia in UK, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Dementia Innovation, Dementia Research, Dementia Research Champions Group, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Epidemiology, Estimation of Future Cases of Dementia: From Males / Females Born in 2015, Forecasting Life Expectancy, Gender (Sex), Gender Differences in Diagnosis Rates, Incidence Studies, Life Expectancy, Life Table Data, Life Tables, National Life Tables, Office of Health Economics (OHE), OHE Consulting, OHE: Office of Health Economics, Prevalence, Prevalence of Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Trajectory of Dementia in the UK | Leave a comment

Proceedings of the Third Global Dementia Legacy Event in Japan: Some Early Transcripts (Department of Health / Dementia Challenge / World Dementia Council)

Posted on November 10, 2014 by Dementia and Elderly Care News

Summary The Third Global Dementia Legacy Event, in Tokyo, took place between Wednesday November 5th – 6th 2014. Topics covered included innovative care solutions, assistive technology, and some further discussions about modifiable lifestyle risk factors. The recently launched “Dementias Platform … Continue reading →

Posted in Acute Hospitals, Assistive Technology, Commissioning, Community Care, Department of Health, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Quick Insights, Standards, Telecare, Telehealth, UK, Universal Interest | Tagged Achieving Dementia Friendly Acute care, Alzheimer's Research UK, Assisted Living Technology, Behavioural Risk Factors and Dementia, Benefits of Remote Monitoring, Bio-Computers, Canada, Canadian Consortium on Neurodegeneration in Aging (CCNA), CCNA: Canadian Consortium on Neurodegeneration in Aging, Challenge on Dementia (David Cameron), Challenges and Barriers to Open Data, Chief Scientific Advisor to UK Government, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia and Neurodegenerative Diseases Research Network, Dementia Awareness, Dementia Challenge, Dementia Friendly Acute Hospitals, Dementia Friends, Dementia Friends Programme, Dementia Innovation, Dementia Research Champions Group, Dementia Risk Factors, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Research Platform UK (DPUK), Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, Digital Technology, DPUK: Dementias Platform UK, Elderly Human Rights, Emerging Technology, European Union, G7 Global Dementia Summit, G8 Dementia Summit, Global Action Against Dementia, Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Health Information Technology, Health Technology, Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Home Telehealth, Human Rights, Independence, Independent Living At Home, Information Technology, Innovation for an Ageing Population, Innovation in Care and Prevention (Japan Legacy Event), International Collaborations, International Dementia Research Inventories, International Programmes, Ipad Technology, Japan, Japan Legacy Event, Japan Legacy Event: Innovation in Care and Prevention, Koyoto, Lifestyle Risk Factors, Maintaining Independence, Medical Research Council (MRC), Medical Research Council's UK Dementias Research Platform (UKDP), Medicines and Healthcare Products Regulatory Agency (MHRA), Monitoring Patients Remotely, MRC: Medical Research Council, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Cooperation and Development, Partnership and Collaboration, Partnership Working, Pharmaceutical Industry, Pharmaceutical Regulators, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Professor Sir Mark Walport, Reducing the Incidence of Dementia, Regaining Independence, Remote Care Monitoring, Remote Health Monitoring, Remote Mental Health Support, Research and Innovation, Resource and Incentives, Risk Factors, Risk Factors for Alzheimer's Diseease, Robotic Care for the Elderly, Robotics, Rosa Kornfield-Matte: Independent Expert on Human Rights, Royal Hospital Chelsea, Science and Innovation, Sir Mark Walport, Sir Mark Walport (Wellcome Trust), Smart Home Adaptations, Smart Homes, Smart Housing, Smart Sensors, Staying Independent, Support for Carers, Sustainable Care, Switzerland, Tackling Barriers to Innovation, Technology Enabled Care Services (TECS), Telehealth (Remote Monitoring), Telehealth and Self Care, Telemedicine, Telemonitoring, Therapeutic Robots, Third Global Dementia Legacy Event, Third Global Dementia Legacy Event (Japan: November 2014), Tokyo, Transformational Technologies, Transformative Technology, UK Dementia Platform, Unhealthy Behaviours, Unhealthy Lifestyles, Unhealthy Living, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO), World Health Organization (WHO), Young Innovators | Leave a comment

Dementias Platform UK (Department of Health / Dementia Challenge / World Dementia Council / MRC)

Posted on October 30, 2014 by Dementia and Elderly Care News

Summary A new multimillion-pound platform for dementia research, entitled the “Dementias Platform UK (DPUK)”, has been launched by the Medical Research Council. The aim is to ensure the UK is one of the best places in the world to research dementia. … Continue reading →

Posted in Charitable Bodies, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Parkinson's Disease, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Academia-Industry Partnerships, Age-Related Neurodegenerative and Neurovascular Diseases, Alzheimer's Disease and Dementia, Araclon, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Research Infrastructure Award, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia and Neurodegenerative Diseases Research Network, Dementia Challenge, Dementia Innovation, Dementia Risk Factors, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Research Platform UK (DPUK), Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, DPUK: Dementias Platform UK, Dr John Gallacher: University of Cardiff, George Freeman: Former Life Sciences Minister, Global Action Against Dementia, Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, GSK, Incentives and Investment, Incentives for Drug Development, Integrated Development Pathway, International Collaborations, International Dementia Research Inventories, International Programmes, IXICO, Janssen Research & Development, Johnson & Johnson Innovation, Medical Research Council (MRC), MedImmune (AstraZeneca), Motor Neurone Disease, MRC Dementias Research Platform UK (DPUK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, NIHR Dementia and Neurodegenerative Diseases Research Network (DeNDRoN), NIHR-MRC Dementia Deep and Frequent Phenotyping, Partnership Working, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Research and Innovation, Resource and Incentives, SomaLogic, WDC: World Dementia Council, World Dementia Council | Leave a comment

World Dementia Council’s Newsletter: Issue No.2 (World Dementia Council)

Posted on September 12, 2014 by Dementia and Elderly Care News

Summary The World Dementia Envoy, Dr Dennis Gillings, has published the second edition of the World Dementia Council Newsletter. This is available in English currently. Translations into other languages are expected to follow shortly. Full Text Link Reference Second World … Continue reading →

Posted in Department of Health, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Academia-Industry Partnerships, Academia-Industry Partnerships (Canada and France Co-Led), Academia-Industry Synergies, Alzheimer’s Association International Conference (2014), Big Data, Canada-France Legacy Event, Challenge on Dementia (David Cameron), Collaborative Projects, Cross-Sector Partnerships, Daisy Acosta: World Dementia Council Member, Dementia Challenge, Dementia Innovation, Dementia Research, Dennis Gillings: Former World Dementia Envoy, Finance, France / Canada Legacy Event, George Vradenburg: President and Chairman of the Vradenburg Foundation and US Against Alzheimer’s, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Dementia Legacy Event Speech (Dr Gillings), Harry Johns: President and CEO of Alzheimer’s Association, Harry Johns: World Dementia Council Member, Incentives and Investment, Joël Ménard: Professor of Public Health Faculty of Medicine Paris-Descartes, Lifestyle Risk Factors, Meera Pattabiraman: World Dementia Council Member, Modifiable Risk Factors, OECD, Open Data and Big Data, Open Science, Partnership, Partnership and Collaboration, Partnership Working, Philippe Amouyel: World Dementia Council Member, Prime Minister’s Dementia Challenge, Professor Philippe Amouyel: EU Joint Programme on Neurodegenerative Disease Research, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Risk Factors, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), Second World Dementia Council Meeting Communique, Tonio Borg: EU Health Commissioner, WDC: World Dementia Council, World Dementia Council Members, World Dementia Council Newsletter, World Dementia Envoy, Yves Leterme: Former Deputy Secretary-General of the OECD | Leave a comment

Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)

Posted on September 11, 2014 by Dementia and Elderly Care News

Summary Canada and France are co-hosting the second Global Action Against Dementia Legacy Event in Ottawa (Canada) on September 11th – 12th 2014. This event will explore how to take advantage of partnership working and collaboration between industry and academia, … Continue reading →

Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Universal Interest | Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Academic-Industry Collaborations, Alain Beaudet: President of Canadian Institutes of Health Research (CIHR), Alice Wong: Minister of State (Seniors) in Canada, Alzheimer Society of Canada, AVIESAN: French National Alliance for Life Sciences and Health, •Alzheimer Society of Canada, Big Data, Biotechnology, Canada, Canada's Research Strategy for Alzheimer's Disease, Canada-France Legacy Event, Canadian Institutes of Health Research (CIHR), Challenge on Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia in Canada, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Dennis Gillings: Former World Dementia Envoy, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug-Development Pipeline, Faye Forbes (Living With Dementia), France, Free Open Access Journals, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit Agreements, G8 Summit on Dementia Communique, G8 Summit on Dementia Declaration, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Leadership, Global Outlook, Incentives and Investment, Incentives for Drug Development, Innovation, Innovative Medicines Initiative, Institute of Health and Medical Research (Inserm), International Collaborations, International Programmes, Japan Legacy Event, Knowledge Networks, Knowledge Translation, Massachusetts Biotech Cluster: CONNECT, Matthew Dineen (Carer), Medical Devices, Networks, Networks and Alliances, Neurological Research, OECD Big Data and Sustainability Initiative for Large-Scale Research on Dementia, Open Access, Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, Philippe Zeller: Ambassador of France to Canada, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Regulatory Barriers: Regulatory Environment, Removing Regulatory Barriers, Research and Innovation, Research Networks, Resource and Incentives, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), The Honourable Rona Ambrose: Minister of Health (Canada), UK Legacy Event, USA Legacy Event, Venture Capital (Approach to Research), World Dementia Council, Yves Lévy: French National Institute of Health and Medical Research (Inserm) and Chairman of Aviesan (French National Alliance for Life Sciences and Health Care) | Leave a comment

Blood Test Potentially Able to Predict Alzheimer’s Disease Onset (BBC News / Alzheimer’s & Dementia)

Posted on July 8, 2014 by Dementia and Elderly Care News

Summary Research published in the Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association may indicate a significant step forwards in developing a blood test which could be able to predict the risk of Alzheimer’s Disease onset with 87% accuracy. Research … Continue reading →

Decline in Number of Clinical Trials for Alzheimer’s Disease (BBC News / Alzheimer’s Research & Therapy)

Posted on July 4, 2014 by Dementia and Elderly Care News

Summary More than 99% of drug trials for Alzheimer’s Disease during the past decade have failed. An article in the Alzheimer’s Research & Therapy journal discusses an issue which was perhaps the key focus of the Global Dementia Legacy Event. … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Standards, Universal Interest | Tagged Alzheimer’s Disease Clinical Trials, Amyloid Cascade Hypothesis, Anti-Amyloid Combination Therapy, Antidementia Drugs, Aston University, BBC Health News, Big Pharma, Brain Research, Cleveland Clinic Lou Ruvo Center for Brain Health: Las Vegas, Clinical Trials and Treatment Assessments, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Incentives for Drug Development, Neurological Research, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, R&D Productivity, Touro University Nevada College of Osteopathic Medicine, Translational Research | Leave a comment

Defeat Dementia Campaign (Alzheimer’s Research UK)

Posted on June 21, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK’s “Defeat Dementia” campaign was announced at the Global Dementia Legacy Event on June 19th 2014. Commitments included in the Defeat Dementia programme include: The launch of the Alzheimer’s Research UK Stem Cell Research Centre. There is a £2 … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Carers (mostly), For Researchers (mostly), In the News, Management of Condition, Quick Insights, UK, Universal Interest | Tagged Alzheimer’s Research UK Stem Cell Research Centre, Charitable Funding, Collaborative Projects, Cross-Sector Partnerships, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Dementia Challenge, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Research: UK Impact, Drug Discovery Institutes, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, Knowledge Networks, Knowledge Translation, Networks, Networks and Alliances, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Philanthropic Funding, Philanthropy, Research Networks, Stem Cell Research, Stem Cell Research Centre, Translational Research, University College London, University of Cambridge | Leave a comment

Tag Archives: Dementia Innovation

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)

Blood Test Potentially Able to Predict Alzheimer’s Disease Onset (BBC News / Alzheimer’s & Dementia)

Decline in Number of Clinical Trials for Alzheimer’s Disease (BBC News / Alzheimer’s Research & Therapy)

Defeat Dementia Campaign (Alzheimer’s Research UK)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites